Chemotherapy Effect, Distress, Emotional, Lung Cancer, Quality of Life (QOL)
Conditions
Keywords
cancer, chemotherapy, immersive, virtual reality, lung cancer, quality of life, symptom, side-effect
Brief summary
Lung cancer is one of the types of cancer with a high incidence and mortality rate in the world and in our country. Frequently used protocols in the chemotherapy treatment of lung cancer are the Platinum-based drugs. The main side effects of this chemotherapy protocols are nausea, vomiting, neutropenia and fatigue. The side effects of cancer and chemotherapy cause patients to experience distress and their quality of life is adversely affected. Some non-pharmacological methods such as meditation, breathing exercises, and massage can be used to manage the symptoms experienced by patients due to chemotherapy for supportive care. One of these methods is virtual reality. In addition, audio-visual (video) therapy methods are other methods that can be used in the symptom management of these patients. In this study, the effect of interactive/immersive virtual reality intervention and relaxant video intervention on symptom severity, distress level and quality of life of patients diagnosed with lung cancer will be evaluated. Patients will be assigned to 3 groups: virtual reality intervention group (VR), relaxant video application group (RV) and control group (CG) by stratified randomization according to the disease stage and drug type. During the chemotherapy treatment, the patients will take interactive/immersive virtual reality (VR group) or relaxant video application (RV group) consisting of nature-themed scenarios. The interventions will be done 2 times and about 20 minutes in the first day of each chemotherapy cycle, in total 2 cycles. The control group will receive routine nursing care. Research data will be collected at different intervals during the chemotherapy course with the Patient Information Form (only once), the Edmonton Symptom Assessment Scale, the NCCN Distress Thermometer, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Patient Follow-up Form and will be analyzed with the IBM SPSS program.
Detailed description
Lung cancer is one of the types of cancer with a high incidence and mortality rate in the world and in our country. Frequently used protocols in the chemotherapy treatment of lung cancer are the Platinum-based drugs. The main side effects of this chemotherapy protocols are nausea, vomiting, neutropenia and fatigue. The side effects of cancer and chemotherapy cause patients to experience distress and their quality of life is adversely affected. In addition to pharmacological approaches, some non-pharmacological methods such as meditation, breathing exercises, and massage can be used to manage the symptoms experienced by patients due to chemotherapy. One of these methods is the virtual reality application, which has started to be used in the field of health with the developing technology, allowing individuals to experience another reality where they are. In addition, audio-visual (video) therapy methods are other methods that can be used in the symptom management of these patients. It is stated that virtual reality intervention and audio-visual therapies (relaxant video application) have positive effects on cancer patients and patients receiving chemotherapy treatment. In this study, the effect of interactive/immersive virtual reality intervention and relaxant video application on symptom severity, distress level and quality of life of patients diagnosed with lung cancer will be evaluated. Patients diagnosed with lung cancer, receiving chemotherapy treatment for the first time, and whose protocols are Cisplatin+Etoposide, Carboplatin+Etoposide, Paclitaxel+Carboplatin, Docetaxel+Cisplatin, Cisplatin+Pemetrexed, Carboplatin+Pemetrexed, Cisplatin+Vinorelbine, Gemcitabine+Cisplatin/Carboplatin and only Cisplatin, will be included in the study. Patients will be assigned to 3 groups: virtual reality application group (VR), relaxant video application group (RV) and control group (CG) by stratified randomization according to the disease stage and drug type. During the chemotherapy treatment, an interactive/immersive virtual reality intervention (VR group) and relaxant video intervention (RV group) consisting of nature-themed scenarios, which are preferred due to their relaxing effects, will be carried out for 2 times, about 20 minutes, the first day of each chemotherapy cycle, during 2 chemotherapy cycles. The control group will receive routine/standard nursing care. Research data will be collected at different intervals during the chemotherapy cures with the Patient Information Form (only once), the Edmonton Symptom Assessment Scale, the NCCN Distress Thermometer, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Patient Follow-up Form and will be analyzed with the IBM SPSS program.
Interventions
OTHERImmersive Virtual Reality
To apply immersive virtual reality (Virtual Environments)
OTHERRelaxing Videos
To watch relaxing videos including pictures and sounds prepared by researcher
Sponsors
Hacettepe University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Three-Arm Randomised Controlled Trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* are over 18 years old, * diagnosed with lung cancer, * will receive chemotherapy for the first time, * will receive at least 2 cycles of chemotherapy treatment * agree to participate in the study * ECOG performance status of 2 or less
Exclusion criteria
* Having a cognitive and psychiatric disorder and diagnosis, * Having brain metastasis or chronic disease related to the head-brain region, * Having vision-hearing problems, * Having epilepsy, vertigo, chronic severe headache, dizziness problems, * Having a history of virtual reality, simulator or motion sickness, * Having/declaring that he/she has open area, underwater, specific animal phobia, * Do not agree to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Edmonton Symptom Assessment Scale (ESAS) | Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total. | Changes on overall score of Edmonton Symptom Assessment Scale. The scale is a numerical scale between 0 and 10 developed to measure each symptom level (total 12 symptoms). Lower scores indicate lower symptom levels. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| National Comprehensive Cancer Network Distress Thermometer (NCCN-DT) | Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total. | Changes on overall score of Distress Scale. The scale is a numerical scale between 0 and 10 developed to measure stress levels. Lower scores indicate lower stress levels. |
| The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) | Before the first intervention session (T1) in the first chemotherapy cycle and after the final intervention session (T4) in the second cycle; same time points in the control group. 2 assessments in total. | Changes on overall score of Quality of Life Scale. The scale is a multi-dimension scale including total 30 questions to measure quality of life level. Minimum score is 0, and maximum score is 100. |
Countries
Turkey (Türkiye)
Outcome results
None listed